Treatment

The intrapatient dose escalation of TCR-anti-CD3 fusion molecules like IMC-F106C effectively targets PRAME-positive cancers, managing safety and achieving clinical activity by reducing tumor burden with minimal off-target effects.

JP2024542682APending Publication Date: 2024-11-15IMMUNOCORE LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024532418
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-08-31
Filing Date
2022-11-30
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

Current TCR bispecific proteins targeting PRAME have not been clinically tested, and existing dosing regimens for TCR-anti-CD3 fusion molecules can lead to dose-limiting toxicities and off-target recognition of normal tissues, complicating their administration.

Method used

A TCR-anti-CD3 fusion molecule, such as IMC-F106C, is administered using an intrapatient dose escalation regimen, with specific doses ranging from 5 μg to 400 μg, administered every 6 to 8 days, to manage safety and exhibit clinical activity while targeting PRAME-positive cancers.

Benefits of technology

The regimen allows for manageable safety profiles and clinical activity, reducing tumor burden and inducing immune responses in PRAME-positive cancers, including melanoma, lung, breast, ovarian, and other solid tumors, with minimal off-target effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024542682000011
    Figure 2024542682000011
  • Figure 2024542682000012
    Figure 2024542682000012
  • Figure 2024542682000013
    Figure 2024542682000013
Patent Text Reader

Abstract

A method of administering a TCR-anti-CD3 fusion molecule for treating a patient with a PRAME-positive cancer is presented. The method comprises administering intravenously to the patient a TCR-anti-CD3 fusion molecule, comprising administering (a) at least one first dose in the range of 5 μg to 40 μg, (b) at least one second dose in the range of 15 μg to 80 μg, and then (c) at least one third dose in the range of 60 μg to 400 μg, where the second dose is higher than the first dose and the third dose is higher than the second dose, and the doses are administered every 6 to 8 days.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to the treatment of cancer, particularly PRAME-positive cancer. In particular, the present invention relates to an anti-CD3 scFv fused to HLA-A * The present invention relates to an administration regimen of a T cell redirecting bispecific therapy (TCR-anti-CD3 fusion molecule) comprising a T cell receptor (TCR) that binds the 02 restricted peptide SLLQHLIGL (SEQ ID NO:1). [Background technology]

[0002] PRAME, or Preferentially Expressed Antigen In Melanoma, was first identified as an antigen overexpressed in melanoma (Non-Patent Document 1). PRAME is also known as CT130, MAPE, and OIP-4, and has the Uniprot accession number P78395. This protein functions as a repressor of retinoic acid receptor signaling (Non-Patent Document 2). PRAME belongs to a family of germline-encoded antigens known as cancer-testis antigens. Cancer-testis antigens are attractive targets for immunotherapeutic intervention, as they typically have limited or no expression in normal adult tissues. PRAME is expressed in many solid tumors, as well as in leukemias and lymphomas (Non-Patent Document 3; Non-Patent Document 4; Non-Patent Document 5; Non-Patent Document 6; Non-Patent Document 7; Non-Patent Document 8; Non-Patent Document 9; Non-Patent Document 10). The PRAME targeted therapy of the present invention may be particularly suitable for the treatment of cancers including, but not limited to, melanoma, lung cancer, breast cancer, ovarian cancer, endometrial cancer, esophageal cancer, bladder cancer, head and neck cancer, uterine cancer, acute myeloid leukemia, chronic myeloid leukemia and Hodgkin's lymphoma.

[0003] The peptide SLLQHLIGL (SEQ ID NO: 1) corresponds to amino acids 425-433 of the full-length PRAME protein and is associated with HLA-A * 02 and presented on the cell surface (Non-Patent Document 11). This peptide-HLA complex provides a useful target for TCR-based immunotherapeutic intervention.

[0004] WO 2018 / 234319 includes SLLQHLIGL-HLA-A * A TCR has been described that binds to the .O2 complex. The TCR is mutated to the alpha and / or beta variable domains of the native PRAME TCR to improve binding affinity and / or binding half-life to the complex, and can be associated (covalently or otherwise) with a therapeutic agent. One such therapeutic agent is an anti-CD3 antibody, or a functional fragment or variant of said anti-CD3 antibody, such as a single chain variable fragment (scFv). The anti-CD3 antibody or fragment may be covalently linked to the C-terminus or N-terminus of the alpha or beta chain of the TCR. The resulting molecule is TCR bispecific.

[0005] TCR bispecific proteins redirect polyclonal T cells to target peptides derived from intracellular or extracellular disease-associated antigens and presented on the cell surface in complex with HLA molecules. This approach utilizes HLA-A peptides derived from gp100 and CD3. * A TCR bispecific protein (tebentafusp) targeting the 02 restricted peptide has been clinically tested in the context of various antigens. Administration of this molecule resulted in OS benefit in uveal melanoma (Non-Patent Document 12). However, such a TCR bispecific protein targeting PRAME has not been clinically tested.

[0006] IMC-F106C is the SLLQHLIGL peptide-HLA-A fused to anti-CD3 scFv. * IMC-F106C is a T cell redirecting bispecific therapy that contains a soluble affinity-enhanced TCR that binds to the 02 complex. The targeting end of IMC-F106C (soluble TCR) targets HLA-A on the surface of cancer cells. * HLA molecules are polymorphic, and approximately 47% of whites in the United States and European countries are HLA-A. * 02 genotype, HLA-A * 02:01 Allele is HLA-A *IMC-F106C is detected in >95% of 02 positive individuals. The effector end of IMC-F106C (anti-CD3 scFv) can bind to CD3 on any T cell and redirect the T cell to produce effector cytokines and / or kill the target-presenting cell. In addition, IMC-F106C-mediated tumor lysis can prime an endogenous anti-tumor immune response. ImmTAC™ (Immune Mobilizing Monoclonal TCRs Against Cancer) molecules such as IMC-F106C are highly potent molecules and have been observed to redirect T cell activity against tumor cell lines presenting as few as 10-50 target peptide:HLA complexes. IMC-F106C binds to HLA-A * It has been shown to selectively redirect T cell activity in the presence of 02:01-positive / PRAME-positive cell lines, resulting in T cell activation and killing of PRAME-positive cancer cells at concentrations as low as 1 pM to 10 pM. * The 02 restricted peptide SLLQHLIGL (SEQ ID NO: 1) is derived from the germline cancer antigen PRAME. IMC-F106C has a TCR alpha chain amino acid sequence of SEQ ID NO: 14 and a TCR beta chain-anti-CD3 amino acid sequence of SEQ ID NO: 16. [Prior art documents] [Non-patent literature]

[0007] [Non-Patent Document 1] Ikeda et al Immunity. 1997 Feb;6(2):199-208 [Non-Patent Document 2] Epping et al., Cell. 2005 Sep 23;122(6):835-47 [Non-Patent Document 3] Doolan et al Breast Cancer Res Treat. 2008 May;109(2):359-65 [Non-Patent Document 4] Epping et al Cancer Res. 2006 Nov 15;66(22):10639-42

Non-Patent Document 5

Non-Patent Document 6

Non-Patent Document 7

Non-Patent Document 8

Non-Patent Document 9

Non-Patent Document 10

Non-Patent Document 11

Non-Patent Document 12

Summary of the Invention

[0008] In a first aspect, the present invention is a TCR-antibody CD3 fusion molecule, wherein a TCR alpha chain amino acid sequence of SEQ ID NO: 14, or a TCR alpha chain amino acid sequence having at least 90%, at least 95% or 100% identity to the amino acid sequence of SEQ ID NO: 14; a TCR β chain-anti-CD3 amino acid sequence of SEQ ID NO: 16, or a TCR β chain-anti-CD3 amino acid sequence having at least 90%, at least 95% or 100% identity to the amino acid sequence of SEQ ID NO: 16; wherein the TCR alpha chain variable domain comprises CDR1, CDR2 and CDR3 having the amino acid sequences of SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:5, respectively, and the TCR beta chain variable domain comprises CDR1, CDR2 and CDR3 having the amino acid sequences of SEQ ID NO:9, SEQ ID NO:10 and SEQ ID NO:11, respectively; 20. A method of treating a PRAME positive cancer in a patient comprising intravenously administering to the patient the TCR-anti-CD3 fusion molecule, (a) at least one first dose in the range of 5 μg to 40 μg; (b) at least one second dose in the range of 15 μg to 80 μg, followed by (c) at least one third dose in the range of 60 μg to 400 μg; wherein the second dose is higher than the first dose and the third dose is higher than the second dose; The dose is administered once every 6 to 8 days, and the TCR-anti-CD3 fusion molecule for use in the method is provided.

[0009] Administration of TCR bispecific reagents may be associated with several risk factors, including cytokine release syndrome (CRS), tumor local inflammation, cytopenia, and off-target T cell activation. In some cases, dose-limiting toxicity may occur at doses below the clinically effective dose. Furthermore, higher doses may result in off-target recognition of normal tissues. The inventors have surprisingly found an intrapatient dose-escalation regimen that allows IMC-F106C to be administered with a manageable safety profile and shows clinical activity.

[0010] The TCR-anti-CD3 fusion molecule used in the present invention comprises an anti-CD3 scFv covalently linked to the N-terminus of the β-chain of the TCR via a linker. This type of molecule is known as ImmTAC™ (Immunomobilizing Monoclonal TCR Against Cancer). ImmTAC™ molecules are engineered to activate a strong T cell response and specifically kill targeted cancer cells. The TCR-anti-CD3 fusion molecule used in the present invention (i.e., ImmTAC targeting PRAME) is described in WO 2018 / 234319, which is incorporated herein by reference in its entirety.

[0011] The terms "TCR-anti-CD3 fusion molecule," "ImmTAC," and "T cell redirecting bispecific therapeutic agent" are used interchangeably herein.

[0012] As used herein, the term "TCR β chain-anti-CD3" refers to the TCR β chain portion of an ImmTAC together with a linker and an anti-CD3 scFv. The term "β chain" is sometimes used in connection with an ImmTAC as an alternative way of referring to this portion of the molecule.

[0013] The sequences referred to herein are as follows: SEQ ID NO: 1 HLA-A * 02 Restricted peptide: SLLQHLIGL SEQ ID NO:2 Amino acid sequence of the TCR alpha chain variable domain of ImmTAC, designated as IMC-F106C. The CDRs (CDR1, CDR2 and CDR3) are underlined and designated in SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:5, respectively, and the framework regions (FR1, FR2, FR3 and FR4) are italicized and designated in SEQ ID NO:27, SEQ ID NO:6, SEQ ID NO:7 and SEQ ID NO:28, respectively. Mutations relative to the native alpha chain are shown in bold. SEQ ID NO:1

[0014] TIFF2024542682000001.tif10170 SEQ ID NO:8 Amino acid sequence of the TCR β chain variable domain of ImmTAC, designated as IMC-F106C. The CDRs (CDR1, CDR2 and CDR3) are underlined and designated in SEQ ID NO:9, SEQ ID NO:10 and SEQ ID NO:11, respectively, and the framework regions (FR1, FR2, FR3 and FR4) are italicized and designated in SEQ ID NO:29, SEQ ID NO:12, SEQ ID NO:13 and SEQ ID NO:30, respectively. Mutations relative to the native β chain are shown in bold. SEQ ID NO:2

[0015] TIFF2024542682000002.tif10170 SEQ ID NO: 14 Amino acid sequence of the TCR alpha chain of ImmTAC, designated as IMC-F106C. The CDRs (CDR1, CDR2 and CDR3) are underlined and are designated in SEQ ID NO: 3, SEQ ID NO: 4 and SEQ ID NO: 5, respectively, and the framework regions (FR1, FR2, FR3 and FR4) are italicized and are designated in SEQ ID NO: 27, SEQ ID NO: 6, SEQ ID NO: 7 and SEQ ID NO: 28, respectively. The constant region is in bold and is designated in SEQ ID NO: 15. Within the constant region, the non-naturally occurring cysteine ​​residue is double underlined (position 48 of the constant region). SEQ ID NO: 3

[0016] TIFF2024542682000003.tif15170 SEQ ID NO: 16 Amino acid sequence of TCR β chain-anti-CD3 of ImmTAC, designated as IMC-F106C. The anti-CD3 scFv (amino acids 1-253) is shown in bold and underlined and is designated in SEQ ID NO: 17. The linker (GGGGS), which appears immediately after the scFv, is shown in light type and is designated in SEQ ID NO: 18. The CDRs (CDR1, CDR2 and CDR3) are shown in underlined type and are designated in SEQ ID NO: 9, SEQ ID NO: 10 and SEQ ID NO: 11, respectively, and the framework regions (FR1, FR2, FR3 and FR4) are shown in italics and are designated in SEQ ID NO: 29, SEQ ID NO: 12, SEQ ID NO: 13 and SEQ ID NO: 30, respectively. The constant region is shown in bold (not underlined) and is designated in SEQ ID NO: 19. Within the constant region, the non-natural cysteine ​​residue is double underlined (position 57 of the constant region). Additional non-natural amino acids at positions 75 and 89 of the constant region are also double underlined.

[0017] TIFF2024542682000004.tif35170

[0018] The CDR sequence of ImmTAC, designated as IMC-F106C:

[0019] TIFF2024542682000005.tif30170

[0020] The framework region sequence of ImmTAC, designated as IMC-F106C:

[0021] TIFF2024542682000006.tif20170

[0022] TIFF2024542682000007.tif20170

[0023] Further linker sequences mentioned herein: GGGSG (SEQ ID NO: 20), GGSGG (SEQ ID NO: 21), GSGGG (SEQ ID NO: 22), GSGGGP (SEQ ID NO: 23), GGEPS (SEQ ID NO: 24), GGEGGGP (SEQ ID NO: 25), and GGEGGGSEGGGS (SEQ ID NO: 26).

[0024] As used herein, a TCR-anti-CD3 fusion molecule comprises: a TCR alpha chain amino acid sequence of SEQ ID NO: 14, or a TCR alpha chain amino acid sequence having at least 90%, at least 95% or 100% identity to the amino acid sequence of SEQ ID NO: 14; a TCR β chain-anti-CD3 amino acid sequence of SEQ ID NO: 16, or a TCR β chain-anti-CD3 amino acid sequence having at least 90%, at least 95% or 100% identity to the amino acid sequence of SEQ ID NO: 16; wherein the TCR alpha chain variable domain comprises CDR1, CDR2 and CDR3 having the amino acid sequences of SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:5, respectively, and the TCR beta chain variable domain comprises CDR1, CDR2 and CDR3 having the amino acid sequences of SEQ ID NO:9, SEQ ID NO:10 and SEQ ID NO:11, respectively.

[0025] In other words, the molecule may have some mutations in the TCR alpha chain amino acid sequence compared to the sequence of SEQ ID NO: 14 (as long as the TCR alpha chain amino acid sequence has at least 90% identity to SEQ ID NO: 14) and / or some mutations in the TCR beta chain-anti-CD3 amino acid sequence compared to the sequence of SEQ ID NO: 16 (as long as the TCR beta chain-anti-CD3 amino acid sequence has at least 90% identity to the amino acid sequence of SEQ ID NO: 16), but the CDRs of the TCR alpha chain must have the amino acid sequences of SEQ ID NO: 3, SEQ ID NO: 4 and SEQ ID NO: 5, respectively, and the CDRs of the TCR beta chain must have the amino acid sequences of SEQ ID NO: 9, SEQ ID NO: 10 and SEQ ID NO: 11, respectively. Thus, the requirement that the TCR alpha chain variable domain comprises CDR1, CDR2 and CDR3 with the amino acid sequences of SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:5 respectively, and that the TCR beta chain variable domain comprises CDR1, CDR2 and CDR3 with the amino acid sequences of SEQ ID NO:9, SEQ ID NO:10 and SEQ ID NO:11 respectively, applies to all aspects and embodiments of the invention described herein. Thus, the TCR alpha chain variable domain comprises CDR1, CDR2 and CDR3 with 100% identity to the amino acid sequences of SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:5 respectively, and the TCR beta chain variable domain comprises CDR1, CDR2 and CDR3 with 100% identity to the amino acid sequences of SEQ ID NO:9, SEQ ID NO:10 and SEQ ID NO:11 respectively.

[0026] Within the scope of the present invention is a phenotypically silent variant of the TCR-anti-CD3 fusion molecule designated as IMC-F106C, having a TCR alpha chain amino acid sequence corresponding to SEQ ID NO: 14 and a TCR beta chain-anti-CD3 amino acid sequence corresponding to SEQ ID NO: 16. As used herein, the term "phenotypically silent variant" is understood to refer to a TCR-anti-CD3 fusion molecule that incorporates one or more additional amino acid changes, including substitutions, insertions and deletions, compared to the sequences of SEQ ID NO: 14 and SEQ ID NO: 16, and which has a similar or the same phenotype as the TCR-anti-CD3 fusion molecule designated as IMC-F106C. For the purposes of this application, the TCR-anti-CD3 fusion molecule phenotype is defined as the antigen binding affinity (K D and / or binding half-life) and antigen specificity. Phenotypically silent variants have a measured K of the TCR-anti-CD3 fusion molecule designated as IMC-F106C when measured under identical conditions (e.g., 25° C. and / or on the same SPR chip). D and / or SLLQHLIGL (SEQ ID NO: 1) HLA-A within 50%, or more preferably within 20%, of the binding half-life * K for 02 complex D and / or binding half-life. Suitable conditions are further provided in Example 3 of WO 2018 / 234319, which is incorporated herein by reference. Antigen specificity is further defined below. As known to those skilled in the art, SLLQHLIGL (SEQ ID NO: 1) HLA-A * It may be possible to produce TCRs that incorporate changes in their variable domains compared to those detailed above, without altering the affinity of interaction with the 02 complex. In particular, such silent mutations may be incorporated within parts of the sequence that are known not to be directly involved in antigen binding. Such minor variations are included within the scope of the present invention.

[0027] Phenotypically silent variants may contain one or more conservative substitutions and / or one or more permissive substitutions. Permissive and conservative substitutions are those that have a measured K of the TCR-anti-CD3 fusion molecule designated as IMC-F106C when measured under the same conditions (e.g., 25° C. and / or on the same SPR chip).D and / or SLLQHLIGL (SEQ ID NO: 1) HLA-A within 50%, or more preferably within 20%, and even more preferably within 10% of the binding half-life * K for 02 complex D and / or may result in changes in binding half-life, except for K D Changes in do not result in affinity below 200 μM (i.e., weaker than 200 μM). By permissive substitutions we mean substitutions that do not fall within the definition of conservative as provided below, but which are nevertheless phenotypically silent.

[0028] The TCR-anti-CD3 fusion molecules used in the present invention may have a similar amino acid sequence and / or contain one or more conservative substitutions that retain the same function (i.e., phenotypically silent as defined above). Those skilled in the art are aware that various amino acids have similar properties and therefore substitutions between them are "conservative". One or more such amino acids of a protein, polypeptide or peptide can often be substituted by one or more other such amino acids without eliminating a desired activity of the protein, polypeptide or peptide.

[0029] Thus, the amino acids glycine, alanine, valine, leucine and isoleucine can often be substituted for one another (amino acids with aliphatic side chains). Of these possible substitutions, it is preferred to use glycine and alanine to substitute for one another (because they have relatively short side chains), and valine, leucine and isoleucine to substitute for one another (because they have larger aliphatic side chains that are hydrophobic). Other amino acids that can often be substituted for one another include phenylalanine, tyrosine and tryptophan (amino acids with aromatic side chains), lysine, arginine and histidine (amino acids with basic side chains), aspartic acid and glutamic acid (amino acids with acidic side chains), asparagine and glutamine (amino acids with amide side chains), and cysteine ​​and methionine (amino acids with sulfur-containing side chains). It should be recognized that amino acid substitutions within the scope of the present invention can be made with naturally occurring or non-naturally occurring amino acids. For example, it is contemplated herein that the methyl group on alanine may be replaced with an ethyl group and / or minor changes may be made to the peptide backbone. Whether natural or synthetic amino acids are used, it is preferred that only L-amino acids are present.

[0030] Substitutions of this nature are often referred to as "conservative" or "semi-conservative" amino acid substitutions. Thus, the invention extends to the use of a TCR-anti-CD3 fusion molecule as described above, but comprising an amino acid sequence with one or more conservative substitutions and / or one or more permissive substitutions in the sequence, such that the TCR α chain amino acid sequence has at least 90% identity (e.g. 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity) to the amino acid sequence of SEQ ID NO: 14, and the TCR β chain-anti-CD3 amino acid sequence has at least 90% identity (e.g. 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity) to the amino acid sequence of SEQ ID NO: 16, with the proviso that the TCR α chain variable domain comprises CDR1, CDR2 and CDR3 having the amino acid sequences of SEQ ID NO: 3, SEQ ID NO: 4 and SEQ ID NO: 5, respectively, and The β chain variable domain comprises CDR1, CDR2 and CDR3 having the amino acid sequences of SEQ ID NO:9, SEQ ID NO:10 and SEQ ID NO:11, respectively.

[0031] "Identity" as known in the art is the relationship between two or more polypeptide sequences or two or more polynucleotide sequences, as determined by comparing the sequences. In the art, identity also means the degree of sequence relatedness between polypeptide sequences or polynucleotide sequences, as the case may be, as determined by the match between strings of such sequences. Although there are several methods for measuring the identity between two polypeptide sequences or two polynucleotide sequences, commonly used methods for determining identity are codified in computer programs. Preferred computer programs for determining identity between two sequences include, but are not limited to, the GCG program package (Devereux, et al., Nucleic Acids Research, 12, 387 (1984)), BLASTP, BLASTN, and FASTA (Atschul et al., J. Molec. Biol. 215, 403 (1990)).

[0032] To compare amino acid sequences, a program such as the CLUSTAL program may be used. This program compares amino acid sequences and finds the optimal alignment by inserting spaces in either sequence as appropriate. For optimal alignment, it is possible to calculate amino acid identity or similarity (conservation of amino acid type in addition to identity). Programs such as BLASTx align the longest stretches of similar sequences and assign a value to the match. It is therefore possible to obtain a comparison in which several regions of similarity are found, each with a different score. Both types of identity analysis are contemplated in the present invention.

[0033] For optimal comparison purposes, the percent identity of two amino acid sequences or two nucleic acid sequences is determined by aligning the sequences (e.g., gaps may be introduced in the first sequence to optimally align the sequences) and comparing the amino acid residues or nucleotides at corresponding positions. The "optimal alignment" is the alignment of two sequences that results in the highest percent identity. The percent identity is determined by the number of identical amino acid residues or nucleotides in the sequences being compared (i.e., % identity = number of identical positions / total number of positions x 100).

[0034] The determination of percent identity between two sequences can be accomplished using mathematical algorithms known to those skilled in the art. An example of a mathematical algorithm for comparing two sequences is the algorithm of Karlin and Altschul (1990) Proc. Natl. Acad. Sci. USA 87:2264-2268, modified as in Karlin and Altschul (1993) Proc. Natl. Acad. Sci. USA 90:5873-5877. The NBLAST and XBLAST programs of Altschul, et al. (1990) J. Mol. Biol. 215:403-410 incorporate such an algorithm. BLAST nucleotide searches can be performed with the NBLAST program, score=100, wordlength=12 to obtain nucleotide sequences homologous to nucleic acid molecules. BLAST protein searches can be performed with the XBLAST program, score=50, wordlength=3 to obtain amino acid sequences homologous to protein molecules used in the present invention. To obtain gapped alignments for comparison purposes, Gapped BLAST may be utilized as described in Altschul et al. (1997) Nucleic Acids Res. 25:3389-3402. Alternatively, PSI-Blast may be used to perform an iterated search that detects distant relationships between molecules (ibid.). When utilizing BLAST, Gapped BLAST, and PSI-Blast programs, the default parameters of the respective programs (e.g., XBLAST and NBLAST) may be used. See http: / / www.ncbi.nlm.nih.gov. Another example of a mathematical algorithm utilized for sequence comparison is the algorithm of Myers and Miller, CABIOS (1989). The ALIGN program (version 2.0), which is part of the CGC sequence alignment software package, incorporates such an algorithm.Other algorithms for sequence analysis known in the art include ADVANCE and ADAM, as described in Torellis and Robotti (1994) Comput. Appl. Biosci., 10:3-5, and FASTA, as described in Pearson and Lipman (1988) Proc. Natl. Acad. Sci. 85:2444-8. Within FASTA, ktup is a control option that sets the sensitivity and speed of the search.

[0035] Mutations, including conservative and permissive substitutions, insertions and deletions, can be introduced into a provided sequence using any suitable method, including, but not limited to, polymerase chain reaction (PCR)-based, restriction enzyme-based cloning, or ligation-independent cloning (LIC) methods. These methods are detailed in many standard molecular biology textbooks. For further details regarding polymerase chain reaction (PCR) and restriction enzyme-based cloning, see Sambrook & Russell, (2001) Molecular Cloning - A Laboratory Manual (3 rd Ed.) CSHL Press. Further information regarding ligation-independent cloning (LIC) can be found in Rashtchian, (1995) Curr Opin Biotechnol 6(1): 30-6. The TCR sequences provided by the present invention can be obtained from solid phase synthesis or any other suitable method known in the art.

[0036] The TCR-anti-CD3 fusion molecule used in the present invention is SLLQHLIGL (SEQ ID NO: 1) HLA-A *The TCR-anti-CD3 fusion molecules used in the present invention have the property of binding to the 02 complex. The TCR-anti-CD3 fusion molecules used in the present invention have been found to strongly recognize this epitope compared to other unrelated epitopes and are therefore particularly suitable as targeting vectors for delivering therapeutic agents or detectable labels to cells and tissues that exhibit these epitopes. The specificity in the context of the TCR-anti-CD3 fusion molecules used in the present invention is that they bind to the antigen-negative HLA-A * 02HLA-A antigen positive, while showing minimal ability to recognize target cells * 02 relating to the ability to recognize target cells.

[0037] Specificity can be measured in vitro, for example in a cellular assay such as that described in Example 6 of WO 2018 / 234319, which is incorporated herein by reference. Recognition can be determined by measuring the level of T cell activation in the presence of the TCR-anti-CD3 fusion molecule and target cells used in the present invention. Minimal recognition of antigen-negative target cells is defined as a T cell activation level that is less than 20%, preferably less than 10%, preferably less than 5%, more preferably less than 1% of the level occurring in the presence of antigen-positive target cells, measured under the same conditions and at a therapeutically relevant concentration. For the TCR-anti-CD3 fusion molecule used in the present invention, a therapeutically relevant concentration can be defined as less than 10 nM, for example less than 1 nM or less than 100 pM. Antigen-positive cells can be obtained by peptide pulsing with an appropriate peptide concentration to obtain a level of antigen presentation comparable to cancer cells (e.g., 10 pM, 10 ... -9 M peptide), or which may naturally present said peptide. Preferably, both the antigen positive cells and the antigen negative cells are human cells. Preferably, the antigen positive cells are human cancer cells. The antigen negative cells preferably include those derived from healthy human tissue.

[0038] The specificity may also or alternatively be determined by determining whether the TCR-anti-CD3 fusion molecule is SLLQHLIGL (SEQ ID NO: 1) HLA-A* The ability of the antibody to bind to the peptide-HLA-A02 complex and not to a panel of other peptide-HLA complexes may be determined, for example, by the Biacore method of Example 3 of WO 2018 / 234319, which is incorporated herein by reference. The panel may comprise at least five, preferably at least ten, other peptide-HLA-A02 complexes. * The peptide may contain the HLA-A complex. Another peptide may share a low level of sequence identity with SEQ ID NO:1 and may be naturally presented. Another peptide may be derived from a protein expressed in healthy human tissue. * Binding to the 02 complex may be at least 2-fold stronger, more preferably at least 10-fold, or at least 50-fold or at least 100-fold stronger, and even more preferably at least 400-fold stronger, than other naturally presented peptide-HLA complexes.

[0039] Another or further approach to determine TCR specificity may be to identify peptide recognition motifs of the TCR using serial mutagenesis, e.g., alanine scanning. Residues that form part of the binding motif are those that cannot tolerate substitutions. Non-tolerant substitutions may be defined as peptide positions where the binding affinity of the TCR is reduced by at least 50%, or preferably at least 80%, compared to the binding affinity for the non-mutated peptide. Such approaches are further described in Cameron et al., (2013), Sci Transl Med. 2013 Aug 7; 5 (197): 197ral03 and WO2014096803. TCR specificity in this case may be determined by identifying alternative motif-containing peptides, particularly alternative motif-containing peptides in the human proteome, and testing these peptides for binding to the TCR. Binding of the TCR to one or more alternative peptides may indicate a lack of specificity. In this case, further testing of TCR specificity through cellular assays may be required.

[0040] A preferred embodiment of the TCR anti-CD3 fusion molecule used in the present invention comprises a TCR alpha chain amino acid sequence having at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity to the amino acid sequence shown in SEQ ID NO: 14, and a TCR beta chain-anti-CD3 amino acid sequence having at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity to the amino acid sequence shown in SEQ ID NO: 16, insofar as the TCR alpha chain variable domain comprises CDR1, CDR2 and CDR3 having the amino acid sequences of SEQ ID NO: 3, SEQ ID NO: 4 and SEQ ID NO: 5, respectively, and the TCR beta chain variable domain comprises CDR1, CDR2 and CDR3 having the amino acid sequences of SEQ ID NO: 9, SEQ ID NO: 10 and SEQ ID NO: 11, respectively. Thus, the TCR anti-CD3 fusion molecules used in the present invention may differ in regions other than the CDRs.

[0041] For example, a TCR anti-CD3 fusion molecule for use in the present invention may comprise a TCR α chain framework 1 region (FR1) amino acid sequence having at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity to the amino acid sequence set forth in SEQ ID NO:27, and / or a TCR α chain framework 2 region (FR2) amino acid sequence having at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity to the amino acid sequence set forth in SEQ ID NO:6, and / or a TCR α chain framework 2 region (FR2) amino acid sequence having at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity to the amino acid sequence set forth in SEQ ID NO:7. It may comprise an alpha chain framework 3 region (FR3) amino acid sequence, and / or a TCR alpha chain framework 4 region (FR4) amino acid sequence having at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity to the amino acid sequence set forth in SEQ ID NO: 28. For example, the alpha chain FR1 and / or FR2 and / or FR3 and / or FR4 regions may each contain one or more, such as one, two or three conservative substitutions and / or up to three permissive substitutions.

[0042] The TCR anti-CD3 fusion molecule used in the present invention may alternatively or additionally comprise a TCR β chain framework 1 region (FR1) amino acid sequence having at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity to the amino acid sequence shown in SEQ ID NO:29, and / or a TCR β chain framework 2 region (FR2) amino acid sequence having at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity to the amino acid sequence shown in SEQ ID NO:12, and / or a TCR β chain framework 2 region (FR2) amino acid sequence having at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity to the amino acid sequence shown in SEQ ID NO:13. It may comprise a β chain framework 3 region (FR3) amino acid sequence, and / or a TCR β chain framework 4 region (FR4) amino acid sequence having at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity to the amino acid sequence set forth in SEQ ID NO: 30. For example, the β chain FR1 and / or FR2 and / or FR3 and / or FR4 regions may each contain one or more, such as one, two or three conservative substitutions and / or up to three permissive substitutions.

[0043] A TCR anti-CD3 fusion molecule for use in the present invention may alternatively or additionally comprise a TCR alpha chain variable domain amino acid sequence having at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity to the amino acid sequence set forth in SEQ ID NO: 2 and / or a TCR beta chain variable domain amino acid sequence having at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity to the amino acid sequence set forth in SEQ ID NO: 8. For example, a TCR-anti-CD3 fusion molecule may comprise a TCR alpha chain variable domain having the amino acid sequence of SEQ ID NO: 2 and a TCR beta chain variable domain having the amino acid sequence of SEQ ID NO: 8. Alternatively, the TCR-anti-CD3 fusion molecule may comprise a TCR α chain variable domain having one or more mutations, such as one, two or three conservative substitutions and / or up to three permissible substitutions, compared to the amino acid sequence of SEQ ID NO:2, and / or a TCR β chain variable domain having one or more mutations, such as one, two or three conservative substitutions and / or up to three permissible substitutions, compared to the amino acid sequence of SEQ ID NO:8.

[0044] The TCR anti-CD3 fusion molecule used in the present invention may alternatively or additionally comprise a TCR alpha chain constant region amino acid sequence having at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity to the amino acid sequence shown in SEQ ID NO: 15, and / or a TCR beta chain constant region amino acid sequence having at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity to the amino acid sequence shown in SEQ ID NO: 19. For example, the TCR alpha chain constant region may have one, two or three conservative substitutions and / or up to three permissive substitutions compared to the amino acid sequence of SEQ ID NO: 15. For example, the TCR beta chain constant region may have one, two or three conservative substitutions and / or up to three permissive substitutions compared to the amino acid sequence of SEQ ID NO: 19.

[0045] Alternatively or additionally, the anti-CD3 scFv in the TCR anti-CD3 fusion molecule used in the present invention may comprise an amino acid sequence having at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity to the amino acid sequence shown in SEQ ID NO:17.

[0046] In the TCR anti-CD3 fusion molecules used in the present invention, the TCR β chain is linked to the anti-CD3 antibody sequence via a linker. The amino acid sequence of the linker may be selected from the group consisting of GGGGS (SEQ ID NO: 18), GGGSG (SEQ ID NO: 20), GGSGG (SEQ ID NO: 21), GSGGG (SEQ ID NO: 22), GSGGGP (SEQ ID NO: 23), GGEPS (SEQ ID NO: 24), GGEGGGP (SEQ ID NO: 25) and GGEGGGSEGGGS (SEQ ID NO: 26). Typically, the linker sequence is GGGGS (SEQ ID NO: 18). Alternatively, the linker may have one or more mutations, such as one, two or three conservative substitutions and / or up to three permissive substitutions, compared to any of the linker sequences of SEQ ID NO: 18 and SEQ ID NO: 20 to SEQ ID NO: 26.

[0047] It is therefore understood that any of these embodiments may be combined so long as the resulting TCR-anti-CD3 fusion molecule comprises a TCR alpha chain amino acid sequence having at least 90% identity (e.g. at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity) to the amino acid sequence of SEQ ID NO: 14 and a TCR beta chain-anti-CD3 amino acid sequence having at least 90% identity (e.g. at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity) to the amino acid sequence of SEQ ID NO: 16, the TCR alpha chain variable domain comprises CDR1, CDR2 and CDR3 having the amino acid sequences of SEQ ID NO: 3, SEQ ID NO: 4 and SEQ ID NO: 5, respectively, and the TCR beta chain variable domain comprises CDR1, CDR2 and CDR3 having the amino acid sequences of SEQ ID NO: 9, SEQ ID NO: 10 and SEQ ID NO: 11, respectively.

[0048] A TCR-anti-CD3 fusion molecule for use in the present invention may comprise a TCR alpha chain having an amino acid sequence corresponding to SEQ ID NO: 14 and a TCR beta chain-anti-CD3 amino acid sequence corresponding to SEQ ID NO: 16, which are the TCR alpha chain and TCR beta chain-anti-CD3 amino acid sequences of IMC-F106C, respectively.

[0049] The α chain constant region having the amino acid sequence of SEQ ID NO: 15 includes a modification to the corresponding native / naturally occurring α chain, where amino acid T48 of the constant region is replaced with C48 as shown herein. The β chain constant region having the amino acid sequence of SEQ ID NO: 19 also includes a modification to the native / naturally occurring β chain, where S57 is replaced with C57 as shown herein. These cysteine ​​substitutions to the native α and β chain constant chain sequences allow the formation of a non-native interchain disulfide bond that stabilizes the refolded soluble TCR, i.e., the TCR formed by refolding the extracellular α and β chains (WO 03 / 020763). This non-native disulfide bond facilitates the display of correctly folded TCRs on phage (Li et al., Nat Biotechnol 2005 Mar;23(3):349-54). In addition, the use of a stable disulfide-linked soluble TCR allows for more convenient evaluation of binding affinity and binding half-life. The β chain constant region having the amino acid sequence of SEQ ID NO:19 also contains additional unnatural amino acids at positions 75 (A75) and 89 (D89) as shown herein.

[0050] All sequences referenced in this application are also referenced in WO 2018 / 234319, which is incorporated herein by reference. Table 1 shows how the portions of the ImmTAC molecules and SEQ ID NOs referenced herein correspond to the SEQ ID NOs in WO 2018 / 234319.

[0051] TIFF2024542682000008.tif246170TIFF2024542682000009.tif101170

[0052] The ImmTAC designated as IMC-F106C and described in this application is designated as ImmTAC2 in WO 2018 / 234319.

[0053] In this embodiment of the invention, the TCR-anti-CD3 fusion molecule comprises: (a) at least one first dose in the range of 5 μg to 40 μg; (b) at least one second dose in the range of 15 μg to 80 μg, followed by (c) at least one third dose in the range of 60 μg to 400 μg; wherein the second dose is higher than the first dose and the third dose is higher than the second dose; The dose is administered once every 6 to 8 days.

[0054] The dosing regimen of the present invention is a dose escalation regimen, in which increasing doses of the TCR-anti-CD3 fusion molecule are administered sequentially. The doses are thus administered in a specified order: a first dose, then a second dose, then a third dose. By "first dose" is meant a dose of the TCR-anti-CD3 fusion molecule at a first level within a specified range. By "second dose" is meant a dose of the TCR-anti-CD3 fusion molecule at a second level within a specified range that is higher than the first level. By "third dose" is meant a dose of the TCR-anti-CD3 fusion molecule at a third level within a specified range that is higher than the second level. It will be appreciated that according to the dosing regimen of the present invention, more than one first dose, more than one second dose, and / or more than one third dose may be administered, so that a patient may receive more than three doses of the TCR-anti-CD3 fusion molecule.

[0055] In the present invention, each dose is expressed as a specified weight of therapeutic agent, regardless of whether the same amount of therapeutic agent is administered, regardless of the patient's body weight or calculated by one of the other methods routinely used to calculate the appropriate dosage for a patient, such as weight of therapeutic agent per kg of body weight, body surface area, or lean muscle mass. The specified weight of therapeutic agent is typically administered at weekly intervals, for example, on days 1, 8, 15, 22, etc. of the treatment regimen, although the administration intervals may be longer or shorter. Thus, the doses (each dose, i.e., at least one first dose, at least one second dose, and at least one third dose) are administered once every 6 to 8 days. The doses (i.e., at least one first dose, at least one second dose, and at least one third dose) are preferably administered once every 7 days. The doses may be spaced apart at different intervals. Alternatively, they may be spaced apart at the same intervals.

[0056] The first dose is in the range of 5 μg to 40 μg. The first dose may be in the range of 6 μg to 40 μg, 5 μg to 10 μg, 10 μg to 20 μg, or 10 μg to 30 μg. The first dose is preferably in the range of 10 μg to 30 μg. The dose can be 5μg, 6μg, 7μg, 8μg, 9μg, 10μg, 11μg, 12μg, 13μg, 14μg, 15μg, 16μg, 17μg, 18μg, 19μg, 20μg, 21μg, 22μg, 23μg, 24μg, 25μg, 26μg, 27μg, 28μg, 29μg, 30μg, 31μg, 32μg, 33μg, 34μg, 35μg, 36μg, 37μg, 38μg, 39μg or 40μg. Preferred first doses include 6μg, 15μg or 20μg and can be administered weekly. The first dose is preferably 20μg. The first dose can be administered once. Alternatively, more than one first dose may be administered, for example 2 to 5 first doses, for example 2 first doses. This may be necessary, for example, if the patient experiences an adverse event (AE) after administration of the first dose. In this case, it may be preferable to administer one or more further first doses before titrating to the second dose. If two or more first doses are administered, it is preferable that they are the same. However, they may be different.

[0057] The second dose is in the range of 15μg to 80μg. The second dose may be in the range of 20μg to 80μg, 15μg to 30μg, 30μg to 50μg, 40μg to 70μg, or 50μg to 70μg. The second dose is preferably in the range of 40μg to 70μg. The second dose may be 15μg, 20μg, 25μg, 30μg, 35μg, 40μg, 45μg, 50μg, 55μg, 60μg, 65μg, 70μg, 75μg, or 80μg. Preferred second doses include 20μg, 40μg, 60μg, or 80μg, and may be administered weekly. The second dose is preferably 60μg. The second dose may be administered once. Alternatively, more than one second dose may be administered, for example 2 to 5 second doses, for example 2 second doses. Again, this may be necessary, for example, if the patient experiences an adverse event after administration of the second dose. In this case, it may be preferable to administer one or more additional first doses before titrating to the second dose. If two or more second doses are administered, it is preferable that they are the same. However, they may be different.

[0058] Preferably, the first dose is in the range of 10 μg to 30 μg and the second dose is in the range of 40 μg to 70 μg.

[0059] The third dose is in the range of 60 μg to 400 μg. The third dose may be in the range of 80 μg to 400 μg, 70 μg to 250 μg, 60 μg to 100 μg, 100 μg to 200 μg, 150 μg to 300 μg, 70 μg to 90 μg, 140 μg to 180 μg, or 220 μg to 260 μg. For example, the third dose can be in the range of 80μg to 240μg, 150μg to 400μg, 150μg to 330μg, 160μg to 320μg, 200μg to 320μg, 240μg to 320μg, 150μg to 170μg, 190μg to 210μg, 230μg to 250μg, 250μg to 270μg, 290μg to 310μg, or 310μg to 330μg. The third dose can be at least 150μg. The third dose may be 60 μg, 65 μg, 70 μg, 75 μg, 80 μg, 85 μg, 90 μg, 95 μg, 100 μg, 110 μg, 120 μg, 130 μg, 140 μg, 150 μg, 160 μg, 170 μg, 180 μg, 190 μg, 200 μg, 210 μg, 220 μg, 230 μg, 240 μg, 250 μg, 260 μg, 270 μg, 280 μg, 290 μg, 300 μg, 310 μg, 320 μg, 330 μg, 340 μg, 350 μg, 360 μg, 370 μg, 380 μg, 390 μg or 400 μg. A preferred third dose is 80 μg. Another preferred third dose is 160 μg. Further preferred third doses include 200 μg, 240 μg, 260 μg, 300 μg and 320 μg. The third dose can be administered one or more times. Typically, the third dose is administered multiple times, for example once every 6 to 8 days, preferably once every 7 days, until treatment is discontinued. Treatment can be continued for one month or more or one year or more. This continued third dose can be referred to and corresponds to a "maintenance dose".

[0060] Treatment may be stopped, for example, due to unacceptable toxicity or because the patient has shown an unacceptable level of disease progression. Alternatively, treatment may be stopped, for example, because the severity of the patient's symptoms has decreased and / or the tumor has shrunk to a level where treatment with the TCR-anti-CD3 fusion molecule is no longer considered necessary. The decision of whether and when to stop treatment can be determined by the clinician. The same dose can be used subsequently. Alternatively, the dose can be gradually increased. For example, the dose can be 5 μg, 10 μg, 15 μg, 20 μg, 30 μg, 40 μg, or 50 μg higher.

[0061] Any combination of the first, second and third dose ranges as described herein is contemplated. For example, the first dose may range from 6 μg to 40 μg, the second dose may range from 20 μg to 80 μg, and the third dose may range from 80 μg to 400 μg.

[0062] In any combination, the first dose may be in the range of 5 μg to 10 μg, 10 μg to 20 μg, or 10 μg to 30 μg, the second dose may be in the range of 15 μg to 30 μg, 30 μg to 50 μg, or 50 μg to 70 μg, and the third dose may be in the range of 60 μg to 100 μg, 100 μg to 200 μg, 150 μg to 300 μg, 150 μg to The second dose may be in the range of 400 μg, 150 μg to 330 μg, 160 μg to 320 μg, 150 μg to 170 μg, 190 μg to 210 μg, 230 μg to 250 μg, 250 μg to 270 μg, 290 μg to 310 μg, or 310 μg to 330 μg, provided that the second dose is higher than the first dose and the third dose is higher than the second dose.

[0063] The first dose may be 6 μg, the second dose may be 20 μg, and the third dose may be in the range of 80 μg to 120 μg. The first dose may be 6 μg, the second dose may be 20 μg, and the third dose may be 80 μg, 100 μg, or 120 μg. In other words, the first dose may be 6 μg, the second dose may be 20 μg, and the third dose may be 80 μg. The first dose may be 6 μg, the second dose may be 20 μg, and the third dose may be 100 μg. The first dose may be 6 μg, the second dose may be 20 μg, and the third dose may be 120 μg.

[0064] The first dose may be 15 μg, the second dose may be 40 μg, and the third dose may be in the range of 140 μg to 180 μg. The first dose may be 15 μg, the second dose may be 40 μg, and the third dose may be 140 μg, 160 μg, or 180 μg. In other words, the first dose may be 15 μg, the second dose may be 40 μg, and the third dose may be 140 μg. The first dose may be 15 μg, the second dose may be 40 μg, and the third dose may be 160 μg. The first dose may be 15 μg, the second dose may be 40 μg, and the third dose may be 180 μg.

[0065] The first dose can be 20 μg, the second dose can be 60 μg, and the third dose can be at least 150 μg. The first dose can be 20 μg, the second dose can be 60 μg, and the third dose can be in the range of 150 μg to 400 μg, for example 150 μg to 330 μg, 150 μg to 170 μg, 160 μg to 320 μg, 190 μg to 210 μg, 220 μg to 320 μg, 240 μg to 320 μg, 230 μg to 250 μg, 250 μg to 270 μg, 220 μg to 260 μg, 290 μg to 310 μg, or 310 μg to 330 μg.

[0066] The first dose may be 20 μg, the second dose may be 60 μg, and the third dose may be 160 μg, 200 μg, 220 μg, 240 μg, 260 μg, 300 μg, or 320 μg. The first dose may be 20 μg, the second dose may be 60 μg, and the third dose may be 160 μg. The first dose may be 20 μg, the second dose may be 60 μg, and the third dose may be 200 μg. The first dose may be 20 μg, the second dose may be 60 μg, and the third dose may be 220 μg. The first dose may be 20 μg, the second dose may be 60 μg, and the third dose may be 240 μg. The first dose may be 20 μg, the second dose may be 60 μg, and the third dose may be 260 μg. The first dose may be 20 μg, the second dose may be 60 μg, and the third dose may be 300 μg. The first dose may be 20 μg, the second dose may be 60 μg, and the third dose may be 320 μg.

[0067] The first dose may be in the range of 10 μg to 30 μg, the second dose may be in the range of 40 μg to 70 μg, and the third dose may be at least 150 μg. The first dose may be in the range of 10 μg to 30 μg, the second dose may be in the range of 40 μg to 70 μg, and the third dose may be in the range of 150 μg to 400 μg. The first dose may be in the range of 10 μg to 30 μg, the second dose may be in the range of 40 μg to 70 μg, and the third dose may be in the range of 150 μg to 330 μg.

[0068] The first dose may be in the range of 10 μg to 30 μg, the second dose may be in the range of 40 μg to 70 μg, and the third dose may be in the range of 150 μg to 170 μg. The first dose may be in the range of 10 μg to 30 μg, the second dose may be in the range of 40 μg to 70 μg, and the third dose may be 160 μg.

[0069] The first dose may be in the range of 10 μg to 30 μg, the second dose may be in the range of 40 μg to 70 μg, and the third dose may be in the range of 190 μg to 210 μg. The first dose may be in the range of 10 μg to 30 μg, the second dose may be in the range of 40 μg to 70 μg, and the third dose may be 200 μg.

[0070] The first dose may be in the range of 10 μg to 30 μg, the second dose may be in the range of 40 μg to 70 μg, and the third dose may be in the range of 230 μg to 250 μg. The first dose may be in the range of 10 μg to 30 μg, the second dose may be in the range of 40 μg to 70 μg, and the third dose may be 240 μg.

[0071] The first dose may be in the range of 10 μg to 30 μg, the second dose may be in the range of 40 μg to 70 μg, and the third dose may be in the range of 250 μg to 270 μg. The first dose may be in the range of 10 μg to 30 μg, the second dose may be in the range of 40 μg to 70 μg, and the third dose may be 260 μg.

[0072] The first dose may be in the range of 10 μg to 30 μg, the second dose may be in the range of 40 μg to 70 μg, and the third dose may be in the range of 290 μg to 310 μg. The first dose may be in the range of 10 μg to 30 μg, the second dose may be in the range of 40 μg to 70 μg, and the third dose may be 300 μg.

[0073] The first dose may be in the range of 10 μg to 30 μg, the second dose may be in the range of 40 μg to 70 μg, and the third dose may be in the range of 310 μg to 330 μg. The first dose may be in the range of 10 μg to 30 μg, the second dose may be in the range of 40 μg to 70 μg, and the third dose may be 320 μg.

[0074] In a second aspect, the present invention provides a TCR-anti-CD3 fusion molecule comprising: a TCR alpha chain amino acid sequence of SEQ ID NO: 14, or a TCR alpha chain amino acid sequence having at least 90%, at least 95% or 100% identity to the amino acid sequence of SEQ ID NO: 14; a TCR β chain-anti-CD3 amino acid sequence of SEQ ID NO: 16, or a TCR β chain-anti-CD3 amino acid sequence having at least 90%, at least 95% or 100% identity to the amino acid sequence of SEQ ID NO: 16; wherein the TCR alpha chain variable domain comprises CDR1, CDR2 and CDR3 having the amino acid sequences of SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:5, respectively, and the TCR beta chain variable domain comprises CDR1, CDR2 and CDR3 having the amino acid sequences of SEQ ID NO:9, SEQ ID NO:10 and SEQ ID NO:11, respectively; 1. A method of treating a PRAME positive cancer in a patient comprising intravenously administering to the patient a TCR-anti-CD3 fusion molecule, (a) at least one first dose; (b) at least one second dose, followed by (c) at least one third dose in the range of 60 μg to 400 μg; administering the second dose is higher than the first dose and the third dose is higher than the second dose; The dose is administered once every 6 to 8 days, and the TCR-anti-CD3 fusion molecule for use in the method is provided.

[0075] This aspect of the invention relates to a dose escalation administration regimen in which at least one third dose in the range of 60 μg to 400 μg is administered after dose escalation.

[0076] The doses (i.e., each dose, i.e., at least one first dose, at least one second dose, and at least one third dose) are administered once every 6 to 8 days. Preferably, the doses (i.e., at least one first dose, at least one second dose, and at least one third dose) are administered once every 7 days. The doses may be spaced at different intervals. Alternatively, they may be spaced at the same intervals.

[0077] The first and second doses may be determined by a clinician or may be as defined herein in relation to the first aspect of the invention.

[0078] The third dose suitable for the second aspect of the invention is described above in relation to the first aspect of the invention. The third dose is in the range of 60 μg to 400 μg. The third dose may be in the range of 80 μg to 400 μg, 70 μg to 250 μg, 60 μg to 100 μg, 100 μg to 200 μg, 150 μg to 300 μg, 70 μg to 90 μg, 140 μg to 180 μg, or 220 μg to 260 μg. For example, the third dose may be in the range of 80μg to 240μg, 150μg to 400μg, 150μg to 330μg, 160μg to 320μg, 200μg to 320μg, 240μg to 320μg, 150μg to 170μg, 190μg to 210μg, 230μg to 250μg, 250μg to 270μg, 290μg to 310μg, or 310μg to 330μg. The third dose may be at least 150μg. The third dose may be 60 μg, 65 μg, 70 μg, 75 μg, 80 μg, 85 μg, 90 μg, 95 μg, 100 μg, 110 μg, 120 μg, 130 μg, 140 μg, 150 μg, 160 μg, 170 μg, 180 μg, 190 μg, 200 μg, 210 μg, 220 μg, 230 μg, 240 μg, 250 μg, 260 μg, 270 μg, 280 μg, 290 μg, 300 μg, 310 μg, 320 μg, 330 μg, 340 μg, 350 μg, 360 μg, 370 μg, 380 μg, 390 μg or 400 μg. A preferred third dose is 80 μg. Another preferred third dose is 160 μg. More preferred third doses include 200 μg, 240 μg, 260 μg, 300 μg and 320 μg. One or more third doses may be administered. Typically, the third dose is administered multiple times, for example once every 6 to 8 days, preferably once every 7 days, until treatment is discontinued. Treatment may continue for one month or more or one year or more. This continued third dose may be referred to as or correspond to a "maintenance dose".

[0079] Treatment may be stopped, for example, due to unacceptable toxicity or because the patient has shown an unacceptable level of disease progression. Alternatively, treatment may be stopped, for example, because the severity of the patient's symptoms has decreased and / or the tumor has shrunk to a level where treatment with the TCR-anti-CD3 fusion molecule is no longer considered necessary. The decision of whether and when to stop treatment can be determined by the clinician. The same dose can be used subsequently. Alternatively, the dose can be gradually increased. For example, the dose can be 5 μg, 10 μg, 15 μg, 20 μg, 30 μg, 40 μg, or 50 μg higher.

[0080] In the present invention, the TCR-anti-CD3 fusion molecule is administered intravenously (iv), typically by intravenous infusion.

[0081] The TCR-anti-CD3 fusion molecules used in the present invention can be administered after a premedication regimen. As will be appreciated by those skilled in the art, premedication is the administration of a drug prior to the administration of a treatment, intended to counteract potential side effects of the treatment. For example, the TCR-anti-CD3 fusion molecules can be administered after a steroid (corticosteroid) and / or non-steroid based premedication regimen. The steroid may be administered before the administration of the first dose, the second dose and / or the third dose, typically before the administration of the third dose. The steroid can be administered, for example, 15 minutes, 20 minutes, 25 minutes or 30 minutes before the administration of the first dose, the second dose and / or the third dose. The steroid may only be administered if the third dose is 140 μg or greater (e.g., if the third dose is 150 μg, 160 μg, 170 μg, 180 μg, 190 μg, 200 μg, 210 μg, 220 μg, 230 μg, 240 μg, 250 μg, 260 μg, 270 μg, 280 μg, 290 μg, 300 μg, 310 μg, 320 μg, 330 μg, 340 μg, 350 μg, 360 μg, 370 μg, 380 μg, 390 μg or 400 μg) and / or before the first administration of the third dose.

[0082] The steroid may be dexamethasone. Dexamethasone may be administered intravenously and may be given in doses ranging from 4 mg to 6 mg. Higher doses, such as 8 mg, 12 mg or 20 mg, may also be used. Alternative steroids include prednisone, methylprednisolone and hydrocortisone.

[0083] Other premedications that may be used in combination with the dosing regimen of the present invention include: Paracetamol (typically given orally at 1 g or equivalent), Ibuprofen (typically administered orally at 600 mg to 800 mg or equivalent), diphenhydramine (typically given as 50 mg orally), non-sedating antihistamines such as cetirizine (typically 10 mg orally) or loratadine (typically 10 mg orally); Antiemetics such as ondansetron (typically 8 mg given orally or intravenously), Intravenous fluids (typically administered in the range of 0.5L to 1L), This is to reduce the risk of hypotension, especially if the patient is experiencing dehydration, poor oral intake and / or nausea / vomiting.

[0084] Any of these premedications can be used alone or in combination. The premedication(s) can be administered before the administration of the first dose, the second dose and / or the third dose, typically before the administration of the third dose. The premedication(s) can be administered, for example, 15 minutes, 20 minutes, 25 minutes or 30 minutes before the administration of the first dose, the second dose and / or the third dose. If the patient develops adverse events related to any of these premedications, a reduced dose may be given. For example, a dose of 25 mg of diphenhydramine can be administered.

[0085] The TCR-anti-CD3 fusion molecules used in the present invention can be administered as a monotherapy. Alternatively, the TCR-anti-CD3 fusion molecules can be administered in combination with one or more anti-cancer therapeutic agents, preferably immunomodulatory or chemotherapeutic agents. Such anti-cancer or chemotherapeutic agents include: Checkpoint inhibitors, such as agents that target PD-1 or PD-L1, such as atezolizumab (TECENTRIQ™) (e.g., 1200 mg every 3 weeks (Q3W)), pembrolizumab (e.g., 400 mg every 6 weeks (Q6W)), nivolumab, avelumab, and durvalumab, and agents that target CTLA-4, such as ipilimumab and tremelimumab; chemotherapy drugs such as dacarbazine and temozolomide; Immunotherapeutic agents such as interleukin-2 (IL-2) and interferon (IFN); BRAF inhibitors such as vemurafenib and dabrafenib, MEK inhibitors such as trametinib, TGF-β inhibitors such as galunisertib, MET kinase inhibitors such as merestinib, angiogenesis inhibitors such as bevacizumab (Avastin™); Gemcitabine (e.g. 1000 mg / m 2 3 weeks on / 1 week off), as well as Other TCR-anti-CD3 fusion molecules such as tebentafusp; Examples include:

[0086] Anti-cancer or chemotherapeutic agents can be administered according to standard guidelines or recommendations, or according to the manufacturer's prescribing information.

[0087] The TCR-anti-CD3 fusion molecule can be administered in combination with a checkpoint inhibitor, which can reduce immune suppression in the tumor microenvironment, enhance the initial activity of IMC-F106C, and / or prevent T cell exhaustion, thereby prolonging the effectiveness of the emerging anti-tumor immune response. The TCR-anti-CD3 fusion molecule can also overcome an important resistance mechanism to checkpoint inhibitors by promoting the recruitment of polyclonal T cells to tumors.

[0088] The TCR-anti-CD3 fusion molecule used according to the present invention can be administered in combination with another TCR-anti-CD3 fusion molecule, i.e., a TCR-anti-CD3 molecule that contains a TCR that binds to a different peptide-MHC complex. Other fusion molecules may contain a TCR that binds to a gp100 peptide-MHC complex. For example, the TCR-anti-CD3 fusion molecule used according to the present invention can be administered in combination with tebentafusp. Tebentafusp can be administered once a week by intravenous infusion according to its current prescription information.

[0089] A preferred combination therapy uses atezolizumab in combination with a TCR-anti-CD3 fusion molecule described herein, which is typically administered by intravenous infusion, e.g., 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks, according to current prescribing information.

[0090] Another preferred combination therapy uses pembrolizumab in combination with a TCR-anti-CD3 fusion molecule described herein, which is typically administered by intravenous infusion, e.g., 200 mg every 3 weeks or 400 mg every 6 weeks, according to current prescribing information.

[0091] The TCR-anti-CD3 fusion molecule may be administered sequentially in combination with other therapeutic agents. The TCR-anti-CD3 fusion molecule may be administered alone in the first and subsequent doses, and then additional therapeutic agents may be added, or vice versa. In embodiments of the invention in which the TCR-anti-CD3 fusion molecule is administered in combination with another anti-cancer therapeutic agent, the TCR-anti-CD3 fusion molecule may be administered alone in the first and second weeks, and the other anti-cancer therapeutic agent may be added in the third and subsequent weeks. For example, atezolizumab is typically administered when the patient reaches the third dose of the TCR-anti-CD3 fusion molecule. Typically, atezolizumab is administered prior to administration of the TCR-anti-CD3 fusion molecule. Administration of the TCR-anti-CD3 fusion molecule, typically by intravenous infusion, may begin, for example, 30 minutes after the infusion of atezolizumab.

[0092] Combination therapy may result in an increased risk of immune-related toxicity, such as CRS. Therefore, a dose of TCR-anti-CD3 fusion molecule may be given initially as a single agent prior to combination administration. Administration of one or more additional anti-cancer therapeutic agents may be performed beginning at week 3.

[0093] The TCR-anti-CD3 fusion molecule may be provided as part of a pharmaceutical composition (e.g., a sterile pharmaceutical composition) together with one or more pharma- ceutically acceptable carriers or excipients for administration to a patient. The composition may be provided in a unit dosage form, typically provided in a sealed container, and may be provided as part of a kit. Such a kit will usually (but not necessarily) include instructions for use. The kit may include a plurality of the unit dosage forms described above.

[0094] The pharmaceutical composition may be of any type suitable for intravenous administration. Such compositions may be prepared by any method known in the pharmaceutical art, for example by mixing the active ingredient with the carrier(s) or excipient(s) under sterile conditions.

[0095] The present invention relates to the treatment of PRAME-positive cancer. By "PRAME-positive cancer" is meant a cancer in which at least some of the cancer cells express PRAME. In other words, a PRAME-positive cancer is a cancer associated with PRAME expression. A cancer may be known to be associated with PRAME expression. For example, the prevalence of PRAME expression may be known to be elevated in cancer, so PRAME expression may not be assessed or may be assessed retrospectively. Alternatively, PRAME expression may be assessed using any method known in the art, including, for example, histological methods, or other quantitative or qualitative measurements, including PCR, RNA expression analysis, and / or kits or sequence panels designed to measure the expression level of PRAME. However, the present invention is not intended to be limited to the treatment of cancers in which PRAME expression can be detected by histological methods. In particular, the present invention is not intended to be limited to the treatment of individual patients in which PRAME expression can be detected by, for example, histological methods. Rather, the present invention is useful for the treatment of cancers and tumor types that are considered PRAME-positive.

[0096] PRAME expression, when detected by histological methods such as immunohistochemistry (IHC), can be quantified using the H-score. Expression of PRAME in individual cells or their subcellular compartments within a tumor is first detected and classified as either positive or negative. Positive cells can be further classified as high, medium or low based on IHC signal intensity. The H-score captures both the intensity and percentage of the biomarker of interest from the IHC image and includes values ​​from 0 to 300, thereby providing a dynamic range to quantify the abundance of a particular marker or gene.

[0097] A variety of cancers and tumor types are considered PRAME positive. PRAME positive cancers include, but are not limited to, melanoma, lung cancer, breast cancer, ovarian cancer, endometrial cancer, esophageal cancer, bladder cancer, head and neck cancer, uterine cancer, acute myeloid leukemia, chronic myeloid leukemia, and Hodgkin's lymphoma. For example, the PRAME positive cancer can be melanoma. The melanoma can be uveal melanoma or cutaneous melanoma. The lung cancer can be non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC). The breast cancer can be triple negative breast cancer (TNBC). The bladder cancer can be urothelial carcinoma. The esophageal cancer can be esophagogastric junction (GEJ) adenocarcinoma. The ovarian cancer can be epithelial ovarian cancer, such as high grade serous ovarian cancer. The cancer can be relapsed, refractory, or intolerant to standard treatment regimens.

[0098] A first aspect of the invention is a TCR-anti-CD3 fusion molecule comprising: a TCR alpha chain amino acid sequence of SEQ ID NO: 14, or a TCR alpha chain amino acid sequence having at least 90%, at least 95% or 100% identity to the amino acid sequence of SEQ ID NO: 14; a TCR β chain-anti-CD3 amino acid sequence of SEQ ID NO: 16, or a TCR β chain-anti-CD3 amino acid sequence having at least 90%, at least 95% or 100% identity to the amino acid sequence of SEQ ID NO: 16; wherein the TCR alpha chain variable domain comprises CDR1, CDR2 and CDR3 having the amino acid sequences of SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:5, respectively, and the TCR beta chain variable domain comprises CDR1, CDR2 and CDR3 having the amino acid sequences of SEQ ID NO:9, SEQ ID NO:10 and SEQ ID NO:11, respectively; 1. A method of treating cancer in a patient comprising intravenously administering to the patient a TCR-anti-CD3 fusion molecule, (a) at least one first dose in the range of 5 μg to 40 μg; (b) at least one second dose in the range of 15 μg to 80 μg, followed by (c) at least one third dose in the range of 60 μg to 400 μg; wherein the second dose is higher than the first dose and the third dose is higher than the second dose; The dose is extended to TCR-anti-CD3 fusion molecules used in the method, administered once every 6 to 8 days.

[0099] A second aspect of the invention is a TCR-anti-CD3 fusion molecule comprising: a TCR alpha chain amino acid sequence of SEQ ID NO: 14, or a TCR alpha chain amino acid sequence having at least 90%, at least 95% or 100% identity to the amino acid sequence of SEQ ID NO: 14; a TCR β chain-anti-CD3 amino acid sequence of SEQ ID NO: 16, or a TCR β chain-anti-CD3 amino acid sequence having at least 90%, at least 95% or 100% identity to the amino acid sequence of SEQ ID NO: 16; wherein the TCR alpha chain variable domain comprises CDR1, CDR2 and CDR3 having the amino acid sequences of SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:5, respectively, and the TCR beta chain variable domain comprises CDR1, CDR2 and CDR3 having the amino acid sequences of SEQ ID NO:9, SEQ ID NO:10 and SEQ ID NO:11, respectively; 1. A method of treating cancer in a patient comprising intravenously administering to the patient a TCR-anti-CD3 fusion molecule, (a) at least one first dose; (b) at least one second dose, followed by (c) at least one third dose in the range of 60 μg to 400 μg; wherein the second dose is higher than the first dose and the third dose is higher than the second dose; The dose is extended to TCR-anti-CD3 fusion molecules used in the method, administered once every 6 to 8 days.

[0100] In any of these aspects, the cancer may be selected from the group consisting of melanoma, lung cancer, breast cancer, ovarian cancer, endometrial cancer, esophageal cancer, bladder cancer, head and neck cancer, uterine cancer, acute myeloid leukemia, chronic myeloid leukemia, and Hodgkin's lymphoma. For example, the cancer may be melanoma. The melanoma may be uveal melanoma or cutaneous melanoma. The lung cancer may be non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC). The breast cancer may be triple negative breast cancer (TNBC). The bladder cancer may be urothelial carcinoma. The esophageal cancer may be esophagogastric junction (GEJ) adenocarcinoma. The ovarian cancer may be epithelial ovarian cancer, such as high-grade serous ovarian cancer.

[0101] The first aspect of the invention also extends to the use of a TCR-anti-CD3 fusion molecule as defined herein in the manufacture of a medicament for the treatment of PRAME positive cancer by intravenous administration of the TCR-anti-CD3 fusion molecule, wherein the treatment of PRAME positive cancer comprises: (a) at least one first dose in the range of 5 μg to 40 μg; (b) at least one second dose in the range of 15 μg to 80 μg, followed by (c) at least one third dose in the range of 60 μg to 400 μg; wherein the second dose is higher than the first dose and the third dose is higher than the second dose; The dose is administered once every 6 to 8 days.

[0102] A second aspect of the invention extends to the use of a TCR-anti-CD3 fusion molecule as defined herein in the manufacture of a medicament for the treatment of PRAME positive cancer by intravenous administration of the TCR-anti-CD3 fusion molecule, wherein the treatment of PRAME positive cancer comprises: (a) at least one first dose; (b) at least one second dose, followed by (c) at least one third dose in the range of 60 μg to 400 μg; wherein the second dose is higher than the first dose and the third dose is higher than the second dose; The dose is administered once every 6 to 8 days.

[0103] The first aspect of the invention also provides a method of treating a PRAME-positive cancer in a patient comprising intravenously administering to the patient a TCR-anti-CD3 fusion molecule, the TCR-anti-CD3 fusion molecule comprising: a TCR alpha chain amino acid sequence of SEQ ID NO: 14, or a TCR alpha chain amino acid sequence having at least 90%, at least 95% or 100% identity to the amino acid sequence of SEQ ID NO: 14; a TCR β chain-anti-CD3 amino acid sequence of SEQ ID NO: 16, or a TCR β chain-anti-CD3 amino acid sequence having at least 90%, at least 95% or 100% identity to the amino acid sequence of SEQ ID NO: 16; wherein the TCR alpha chain variable domain comprises CDR1, CDR2 and CDR3 having the amino acid sequences of SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:5, respectively, and the TCR beta chain variable domain comprises CDR1, CDR2 and CDR3 having the amino acid sequences of SEQ ID NO:9, SEQ ID NO:10 and SEQ ID NO:11, respectively; The method comprises: (a) at least one first dose in the range of 5 μg to 40 μg; (b) at least one second dose in the range of 15 μg to 80 μg, followed by (c) at least one third dose in the range of 60 μg to 400 μg; administering the second dose is higher than the first dose and the third dose is higher than the second dose; The dose will also be expanded to be administered once every 6 to 8 days.

[0104] A second aspect of the invention also provides a method of treating a PRAME-positive cancer in a patient comprising intravenously administering to the patient a TCR-anti-CD3 fusion molecule, the TCR-anti-CD3 fusion molecule comprising: a TCR alpha chain amino acid sequence of SEQ ID NO: 14, or a TCR alpha chain amino acid sequence having at least 90%, at least 95% or 100% identity to the amino acid sequence of SEQ ID NO: 14; a TCR β chain-anti-CD3 amino acid sequence of SEQ ID NO: 16, or a TCR β chain-anti-CD3 amino acid sequence having at least 90%, at least 95% or 100% identity to the amino acid sequence of SEQ ID NO: 16; wherein the TCR alpha chain variable domain comprises CDR1, CDR2 and CDR3 having the amino acid sequences of SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:5, respectively, and the TCR beta chain variable domain comprises CDR1, CDR2 and CDR3 having the amino acid sequences of SEQ ID NO:9, SEQ ID NO:10 and SEQ ID NO:11, respectively; The method comprises: (a) at least one first dose; (b) at least one second dose, followed by (c) at least one third dose in the range of 60 μg to 400 μg; administering the second dose is higher than the first dose and the third dose is higher than the second dose; The dose will also be expanded to be administered once every 6 to 8 days.

[0105] A method of treating a PRAME-positive cancer comprises administering a therapeutically effective amount of a TCR anti-CD3 fusion molecule.

[0106] The TCR anti-CD3 fusion molecules can be formulated into pharmaceutical compositions. These compositions can contain, in addition to the TCR anti-CD3 fusion molecules, one or more pharma- ceutically acceptable excipients, carriers, buffers, stabilizers, or other materials known to those skilled in the art. The compositions can be provided in unit dosage form, generally in a sealed container, and can be provided as part of a kit. Such kits usually (but not necessarily) include instructions for use and can include a plurality of the above unit dosage forms. The pharmaceutical compositions can be in any form suitable for intravenous administration. Such compositions can be prepared by any method known in the pharmaceutical arts, for example by mixing the active ingredient with the carrier(s) or excipient(s) under sterile conditions.

[0107] The administration of the TCR anti-CD3 fusion molecule is preferably a "therapeutically effective amount", which is an amount sufficient to show benefit to the patient. In relation to the first aspect of the invention, the therapeutically effective amount comprises at least one first dose in the range of 5 μg to 40 μg, at least one second dose in the range of 15 μg to 80 μg, and at least one third dose in the range of 60 μg to 400 μg. In relation to the second aspect of the invention, the therapeutically effective amount comprises at least one first dose and / or at least one second dose, which are determined by the clinician taking into account the state of the disease and the state of the patient to be treated. In relation to the second aspect of the invention, the therapeutically effective amount comprises at least one third dose in the range of 60 μg to 400 μg.

[0108] Administration of TCR anti-CD3 fusion molecules to patients can result in improved patient outcomes, such as increased progression-free survival or overall survival. Administration of TCR anti-CD3 fusion molecules to patients can result in a reduction in overall tumor size as determined by RECIST v1.1 criteria (Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-247).

[0109] During the course of a clinical trial, including after administration of a TCR anti-CD3 fusion molecule to a patient, the patient may be identified as having a partial response (PR), a complete response (CR), or as having stable disease (SD) or progressive disease (PD).

[0110] Preferred features of each aspect of the invention apply mutatis mutandis with respect to each of the other aspects. It will be understood that certain features of the invention described for clarity in the context of separate embodiments may also be provided in combination in a single embodiment. Conversely, various features of the invention described for brevity in the context of a single embodiment may also be provided separately or in any suitable subcombination. All combinations of the embodiments relating to the TCR-anti-CD3 fusion molecules for use and methods for treating PRAME-positive cancer are specifically embraced by the present invention and are disclosed herein as if each and every combination were individually and expressly disclosed. The prior art documents referred to herein are incorporated by reference to the fullest extent permitted by law. Citation or identification of any document in this application is not an admission that such document is available as prior art to the present invention. [Brief description of the drawings]

[0111] [Figure 1] FIG. 1 shows the dose escalation cohorts described in the Examples. The first panel shows a dose escalation cohort of 37 patients, and the second panel shows a dose escalation cohort of 55 patients who were enrolled at a later time point. Each box represents a separate cohort. Doses are represented as "X / Y / Zmcg", where X is the first dose (in micrograms), Y is the second dose (in micrograms), and Z is the third dose (in micrograms). The first dose was administered on day 1, the second dose on day 8, and the third dose on day 15. [Diagram 2] Figure 1 shows the number of patients and their cancer types enrolled in each cohort. In the first panel, a total of 36 patients were enrolled. In the second panel, a total of 55 patients were enrolled. [Diagram 3] FIG. 1 shows a summary of adverse events (AEs) associated with administration of IMC-F106C in the dose escalation cohort in which 37 patients were enrolled. [Figure 4] FIG. 1 shows the pharmacodynamic activity of IMC-F106C in 37 enrolled patients with respect to absolute lymphocyte count (ALC) and body temperature. [Diagram 5] FIG. 1 shows the pharmacodynamic activity of IMC-F106C in 37 enrolled patients with respect to the production of cytokines (A) IL-6 and IFNg. [Figure 6] 1 shows the percentage change in target lesion size over time following administration of IMC-F106C, indicating the cohort to which the patient belongs (according to the cohort defined dose, CDD, i.e., their third dose). [Figure 7] Figure 1 shows the percentage change in target lesion size for individual patients after administration of IMC-F106C. The figure indicates the cohort (by CDD) to which the patient belongs and their cancer type: cutaneous melanoma = CM, metastatic uveal melanoma = mUM, serous ovarian cancer = sOC, endometrial cancer = EC. [Figure 8] FIG. 13 shows the percent change in individual target lesion size following administration of IMC-F106C for cohort (by CDD). [Figure 9] Figure 1 shows a summary of adverse events (AEs) associated with administration of IMC-F106C in 55 enrolled patients. AEs are listed in two separate categories: those associated with receiving a third dose ranging from 0.3mcg to 10mcg and those associated with receiving a third dose ranging from 20mcg to 320mcg. Events marked with * include events reported as symptoms or signs of CRS. † indicates safety demonstrated with the intended escalating target dose on day 15. One patient out of 37 received a single dose of 2mcg and did not reach a target dose of 20mcg or greater. [Figure 10] FIG. 1 shows the pharmacodynamic activity of IMC-F106C with respect to IFNγ induction in peripheral blood and lymphocyte count measurements in peripheral blood. [Figure 11]Figure 1 shows the best percent change from baseline in RECIST response for different tumor types. Ovarian cancer patients with unconfirmed PR (uPR), marked with †, continued treatment at the time of analysis and were still eligible for confirmation. PRAME expression in tumors marked with ‡ was assessed by immunohistochemistry (IHC) H-score. In the figure, "Endo" corresponds to endometrial cancer, "NSCLC" corresponds to non-small cell lung cancer, and "TNBC" corresponds to triple-negative breast cancer. Two patients (one NSCLC and one serous ovarian cancer, marked with *) discontinued treatment due to progressive disease (PD). [Figure 12] 1 is a spider plot showing the percent change in target lesion size over time (in weeks) relative to baseline measurements for the various tumors indicated. Each line represents the change over time for an individual patient. NSCLC corresponds to non-small cell lung cancer. [Figure 13] Figure 1 shows the best log reduction in circulating tumor DNA in 20 evaluable patients from the IMC-F106C clinical trial. ctDNA was assessed using one of two defined panels depending on tumor type: for uveal melanoma, a custom panel including GNAQ, GNA11, SF3B1, PLCB4, CYSLTR2 and EIF1AX, or the G360™ panel (Guardant Health, Inc.), which includes 73 genes frequently mutated in diverse cancers, as described in the PCT application entitled "Compositions and Methods for Treating Cancer that Demonstrates Decreasing Levels of ctDNA in a Subject," filed August 31, 2022, which is incorporated herein by reference. Tumor types are identified as follows: B, triple-negative breast cancer; C, cutaneous melanoma; ctDNA, circulating tumor DNA; E, endometrial carcinoma; LA, non-small cell lung adenocarcinoma; LS, non-small cell lung squamous carcinoma; O, ovarian carcinoma; U, uveal melanoma; CPI, checkpoint inhibitors; tebe, tebentafusp. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS EXAMPLES

[0112] The invention is further described in the following non-limiting examples.

[0113] Example 1: IMC-F106C-101 Clinical Trial Design This example shows the relationship between HLA-A and PRAME-positive advanced cancer. * Summary of interim results at different time points of the Phase 1 / 2 multicenter, open-label, first-in-human, dose-escalation study of IMC-F106C in 02:01 positive participants ("IMC-F106C-101"). The study was designed to evaluate the safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics and antitumor activity of IMC-F106C as monotherapy and in combination with checkpoint inhibitors (e.g., atezolizumab, pembrolizumab) or in combination with chemotherapeutic agents (e.g., gemcitabine, nab-paclitaxel or PLD).

[0114] IMC-F106C is an immune mobilizing monoclonal T cell receptor against cancer (ImmTAC™), a bispecific protein therapeutic that contains a soluble affinity-enhanced T cell receptor (TCR; targeting domain) fused to an antibody single chain variable fragment that specifically recognizes cluster of differentiation 3 (anti-CD3 scFv; effector domain). IMC-F106C is described in WO 2018 / 234319, which is incorporated herein by reference in its entirety. In WO 2018 / 234319, IMC-F106C is designated as ImmTAC2.

[0115] IMC-F106C TCR targets human leukocyte antigen-A allele 02:01 (HLA-A *IMC-F106C recognizes a complex consisting of a peptide fragment of the melanoma preferentially expressed antigen (PRAME) presented by the CD4+ TCR (CD4+ TCR 02:01). Upon ligation of the soluble TCR, the effector domain can bind to CD3 on any T cell and stimulate the T cell to release effector cytokines and lyse the bound target cell. In addition, tumor cell killing mediated by IMC-F106C can prime an endogenous antitumor immune response.

[0116] PRAME is a cancer-testis antigen that is commonly and highly expressed in a variety of solid and hematological malignancies, including melanoma, ovarian cancer, uterine cancer, small cell and non-small cell lung cancer, triple-negative breast cancer, and urothelial carcinoma.

[0117] The data below were obtained at different time points with successive cohorts in IMC-F106C-101, including the first time point from 36 patients treated in the dose escalation phase of the monotherapy arm of IMC-F106C-101 across multiple dose cohorts, and different time points from 55 patients.

[0118] IMC F106C was administered by IV infusion weekly (Q1W) in 21-day cycles, with each cycle including a first dose on day 1, a second dose on day 8, and a third dose on day 15. IV infusion times were typically 1 hour ± 10 minutes for cycles 1 and 2, and 30 minutes (± 10 minutes) from day 1 of cycle 3.

[0119] Safety assessments included physical examination, vital signs, weight, Eastern Cooperative Oncology Group (ECOG) performance status, hematology, chemistry, coagulation, urinalysis, thyroid function, cytokine testing, pregnancy testing, cardiac testing, and adverse events (AEs) were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0 unless otherwise specified.

[0120] Tumor response was determined locally according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.

[0121] The dose escalation cohorts are shown in FIG. 1. The first panel shows a dose escalation cohort of 37 patients and the second panel shows a dose escalation cohort of 55 patients evaluated at subsequent time points. Each box represents a separate cohort. Doses are represented as "X / Y / Zmcg" where X is the first dose (in micrograms), Y is the second dose (in micrograms), and Z is the third dose (in micrograms). The first dose was administered on day 1, the second dose on day 8, and the third dose on day 15. The second panel of FIG. 1 shows that the 15 / 40 / 160mcg regimen shown in the first panel of FIG. 1 was well tolerated and demonstrated pharmacodynamic and clinical activity, and therefore further escalation to a dose of 30 / 80 / 320mcg was performed. FIG. 2 shows the number of patients enrolled in each cohort and their cancer type.

[0122] Example 2: Safety data and pharmacodynamic activity of IMC-F106C-101 Figure 3 shows a summary of adverse events (AEs) associated with administration of IMC-F106C after dosing in 37 patients. Figure 9 shows a summary of AEs after dosing in 55 patients. IMC-F106C was well tolerated in all cohorts. The most frequent AEs were cytokine-mediated events such as fever, cytokine release syndrome (CRS), chills, and nausea. There were no treatment discontinuations or deaths due to treatment-emergent AEs or grade 5 events. One patient in cohort 5 experienced a dose-limiting toxicity (DLT), which was an increase in aspartate transaminase to grade 2 at the 1 mcg dose of C1D1. Analysis of the 55 patients showed that CRS events were manageable, with the majority occurring in the first three doses. Of the CRS events in the 55 patients, 71% were grade 1, 29% were grade 2, and no grade 3 or higher CRS events were observed. AEs abated over time. In addition, other immune-related AEs typically seen after treatment with checkpoint inhibitors were not observed, and AEs decreased in frequency with repeated dosing.

[0123] Figure 4 shows the pharmacodynamic activity of IMC-F106C with respect to absolute lymphocyte count (ALC) and body temperature. This figure shows that a gradual decline in ALC was observed across all dose levels in the first 37 enrolled patients. Cohorts receiving a third dose of 40mcg or higher had a mean ALC decline of more than 80% during cycle 1. An increase in body temperature was also observed across all dose levels. Patients in the 6 / 20 / 80mcg cohort were given steroid-based premedication.

[0124] Figure 5 shows the pharmacodynamic activity of IMC-F106C with respect to the production of cytokines IL-6 and IFNg. The figure shows that all of the first 37 enrolled patients receiving at least 3mcg of the third dose showed a greater than 5-fold increase in IL-6 production. Similarly, IFNg production was induced in patients receiving at least 3mcg. Patients in the 6 / 20 / 80mcg cohort were given steroid-based premedication.

[0125] Figure 10 shows the strong and consistent pharmacodynamic activity of IMC-F106C at doses of 20mcg and above. In particular, administration of doses of 20mcg and above resulted in consistent and robust induction of IFNγ, a specific marker of T cell activation. Administration of doses of 20mcg and above also resulted in a corresponding decrease in peripheral blood lymphocyte counts, and increased T cell infiltration into tumor sites was observed as early as 28 days after treatment with IMC-F106C. These observations indicate that administration of IMC-F106C at these doses redirects T cells to tumors.

[0126] Example 3: Clinical efficacy and durability of IMC-F106C-101 Interim clinical efficacy data across Cohort 1 through Cohort 8 (first 37 enrolled patients) (only one patient was evaluated in Cohort 8, who did not progress beyond the third dose, C1D15) are shown in Table 2 below.

[0127] TIFF2024542682000010.tif66170

[0128] Table 2 shows that even with such a low dose of IMC-F106C, two patients had a partial response to treatment. Patients with partial responses or stable disease (RECIST) were observed in patients receiving a third dose of 20 mcg or more. Patients with progressive disease were mostly in the cohort receiving a third dose of less than 20 mcg.

[0129] Figure 6 shows the percentage change in target lesion size over time following administration of IMC-F106C in cohorts 1 through 8 (only one patient was evaluated in cohort 8, who did not progress beyond the third dose, C1D15). The figure shows that even at such low doses of IMC-F106C, stable disease was achieved for an extended period of time (i.e., 27 weeks or more) in some patients, indicating a correlation between tumor shrinkage and higher doses. Additionally, the majority of patients with stable disease showed a decrease in the longest diameter of the target lesion.

[0130] Figure 7 shows the percentage change in target lesion size after administration of IMC-F106C. The figure shows the cohort to which the patients belong and their cancer type. The dashed line separates patients who had tumor shrinkage from those who did not. Tumor shrinkage was observed in 42% of patients and correlated with higher doses of IMC-F106C. The majority of patients who had tumor shrinkage were melanoma patients (the largest tumor type enrolled). However, shrinkage was also observed in one-third of ovarian cancer patients.

[0131] FIG. 8 shows the percent change in individual target lesion size following administration of IMC-F106C for the cohort.

[0132] Figures 7 and 8 show that tumor shrinkage was more prevalent in patients receiving a third dose of 20mcg or more. This was despite high tumor burden at screening. Most of these patients experienced shrinkage of most of their target lesions. Nearly all patients had high PRAME H scores, with median H scores over 200 in both tumor shrinkage / tumor growth groups. In the efficacy population cohort of 55 enrolled patients, the median H score was 188 out of 300. Interestingly, in patients who experienced tumor shrinkage, the median tumor burden at baseline was 104mm, indicating that some patients with larger tumor lesions at baseline also derived clinical benefit from IMC-F106C. There was no correlation between baseline tumor burden (by sum of the longest diameter of the target lesions) and change in tumor size after administration of IMC-F106C.

[0133] Figure 11 shows RECIST responses in patients across consecutive cohorts of 55 enrolled patients across multiple tumors. In uveal melanoma, partial responses (PR) were observed in 50% (3 / 6 PR) of evaluable patients. In cutaneous melanoma patients, all of whom had received prior anti-PD1 and ipilimumab treatment, PR was observed in 33% (2 / 6) of evaluable patients. In platinum-resistant serous ovarian cancer, PR was observed in 50% (2 / 4) of evaluable patients. It was notable that responses were also observed in patients who had progressed on prior immunotherapy.

[0134] Figure 12 shows that IMC-F106C produced clinical activity in a variety of tumor types. Notably, patients who showed partial responses (PR) had promising durability as indicated by stable or reduced lesion size over time. Many patients without PR had stable disease over time.

[0135] Figure 13 shows that reduction in circulating tumor DNA was observed across a variety of tumor types. Reduction in ctDNA is a novel early marker of clinical benefit in IMC-F106C-101. Of the 20 evaluable patients, nearly all had reduction in ctDNA, with the majority having a 50% reduction and 25% showing clearance of ctDNA. Four PR patients evaluated for ctDNA had a reduction of 50% or more in ctDNA, including three with complete clearance. Reduction and clearance of ctDNA was generally observed within 1-2 months of treatment.

[0136] Summary of results The above results are the first to demonstrate the therapeutic potential of a soluble bispecific TCR targeting PRAME.IMC-F106C exhibits pharmacodynamic and clinical activity as demonstrated by the results of the IMC-F106C-101 clinical trial.

[0137] The results described herein show that IMC-F106C was well tolerated in humans. In particular, a first dose of 6mcg on day 1, a second dose of 15mcg on day 8, and a third dose of 80mcg on day 15 (6 / 15 / 80mcg cohort) was well tolerated and supported further escalation to higher doses, such as 15 / 40 / 160mcg and 20 / 60 / 240mcg or higher. IMC-F106C was also well tolerated when administered at higher doses of 15 / 40 / 160mcg and 30 / 80 / 320mcg, with clinical activity observed in both cohorts.

[0138] Administration of IMC-F106C (also called PRAME x CD3 ImmTAC) activated T cells. IMC-F10C was well tolerated, with CRS mostly grade 1 and none grade 3 or higher, occurring primarily during the first three doses. Treatment-related adverse events with IMC-F106C were manageable, with no events leading to discontinuation or death. Consistent and robust pharmacodynamic biomarker activity was observed with the third dose or cohort-specified dose (CDD) of IMC-F106C ≥ 20 mcg. In some cases, clinical activity was observed with the third dose or CDD ≥ 20 mcg.

[0139] Treatment with IMC-F106C resulted in durable (up to 9+ months) RECIST PR in multiple tumor types, including patients with cutaneous melanoma that had progressed after prior anti-PD1 and anti-CTLA4, heavily pretreated platinum-resistant ovarian cancer, and uveal melanoma. Benefits in disease control were also observed, including conversion of stable disease (SD) to PR. Nearly all evaluable patients also showed reductions in ctDNA across multiple tumor types, and early reductions appeared to be associated with clinical benefit. Complete ctDNA clearance appeared to be common in melanoma patients receiving effective therapy.

Claims

1. 1. A TCR-anti-CD3 fusion molecule comprising: a TCR alpha chain amino acid sequence of SEQ ID NO: 14, or a TCR alpha chain amino acid sequence having at least 90%, at least 95% or 100% identity to the amino acid sequence of SEQ ID NO: 14; a TCR β chain-anti-CD3 amino acid sequence of SEQ ID NO: 16, or a TCR β chain-anti-CD3 amino acid sequence having at least 90%, at least 95% or 100% identity to the amino acid sequence of SEQ ID NO: 16; wherein the TCR alpha chain variable domain comprises CDR1, CDR2 and CDR3 having the amino acid sequences of SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:5, respectively, and the TCR beta chain variable domain comprises CDR1, CDR2 and CDR3 having the amino acid sequences of SEQ ID NO:9, SEQ ID NO:10 and SEQ ID NO:11, respectively; A method of treating a PRAME-positive cancer in a patient comprising intravenously administering to the patient the TCR-anti-CD3 fusion molecule, (a) at least one first dose ranging from 5 μg to 40 μg; (b) at least one second dose ranging from 15 μg to 80 μg, followed by (c) at least one third dose ranging from 60 μg to 400 μg; wherein the second dose is higher than the first dose and the third dose is higher than the second dose; The TCR-anti-CD3 fusion molecule used in the method, wherein the dose is administered once every 6 to 8 days.

2. 2. A TCR-anti-CD3 fusion molecule for use according to claim 1, comprising an alpha chain amino acid sequence corresponding to SEQ ID NO:14 and a TCR beta chain-anti-CD3 amino acid sequence corresponding to SEQ ID NO:

16.

3. 3. The TCR-anti-CD3 fusion molecule for use according to claim 1 or 2, wherein the first dose is in the range of 5 μg to 10 μg, the second dose is in the range of 15 μg to 30 μg, and the third dose is in the range of 60 μg to 100 μg.

4. 4. The TCR-anti-CD3 fusion molecule for use according to claim 3, wherein said first dose is 6 μg, said second dose is 20 μg and said third dose is 80 μg.

5. 3. The TCR-anti-CD3 fusion molecule for use according to claim 1 or 2, wherein the first dose is in the range of 10 μg to 20 μg, the second dose is in the range of 30 μg to 50 μg, and the third dose is in the range of 100 μg to 200 μg.

6. 6. The TCR-anti-CD3 fusion molecule for use according to claim 5, wherein said first dose is 15 μg, said second dose is 40 μg and said third dose is 160 μg.

7. 3. The TCR-anti-CD3 fusion molecule for use according to claim 1 or 2, wherein the first dose is in the range of 10 μg to 30 μg, the second dose is in the range of 50 μg to 70 μg, and the third dose is in the range of 150 μg to 300 μg.

8. 8. The TCR-anti-CD3 fusion molecule for use according to claim 7, wherein the first dose is 20 μg, the second dose is 60 μg, and the third dose is 240 μg.

9. The TCR-anti-CD3 fusion molecule for use according to claim 1 or 2, wherein the first dose is in the range of 10 μg to 30 μg and the second dose is in the range of 40 μg to 70 μg.

10. 3. The TCR-anti-CD3 fusion molecule for use according to claim 1 or 2, wherein the first dose is in the range of 10 μg to 30 μg, the second dose is in the range of 40 μg to 70 μg, and the third dose is at least 150 μg.

11. 3. The TCR-anti-CD3 fusion molecule for use according to claim 1 or 2, wherein the first dose is in the range of 10 μg to 30 μg, the second dose is in the range of 40 μg to 70 μg, and the third dose is in the range of 150 μg to 400 μg.

12. 3. The TCR-anti-CD3 fusion molecule for use according to claim 1 or 2, wherein the first dose is in the range of 10 μg to 30 μg, the second dose is in the range of 40 μg to 70 μg, and the third dose is in the range of 150 μg to 330 μg.

13. 3. The TCR-anti-CD3 fusion molecule for use according to claim 1 or 2, wherein the first dose is in the range of 10 μg to 30 μg, the second dose is in the range of 40 μg to 70 μg, and the third dose is in the range of 150 μg to 170 μg.

14. 3. The TCR-anti-CD3 fusion molecule for use according to claim 1 or 2, wherein the first dose is in the range of 10 μg to 30 μg, the second dose is in the range of 40 μg to 70 μg, and the third dose is 160 μg.

15. 3. The TCR-anti-CD3 fusion molecule for use according to claim 1 or 2, wherein the first dose is 20 μg, the second dose is 60 μg and the third dose is 160 μg.

16. 3. The TCR-anti-CD3 fusion molecule for use according to claim 1 or 2, wherein the first dose is in the range of 10 μg to 30 μg, the second dose is in the range of 40 μg to 70 μg, and the third dose is in the range of 190 μg to 210 μg.

17. 3. The TCR-anti-CD3 fusion molecule for use according to claim 1 or 2, wherein the first dose is in the range of 10 μg to 30 μg, the second dose is in the range of 40 μg to 70 μg, and the third dose is 200 μg.

18. 3. The TCR-anti-CD3 fusion molecule for use according to claim 1 or 2, wherein the first dose is 20 μg, the second dose is 60 μg and the third dose is 200 μg.

19. 3. The TCR-anti-CD3 fusion molecule for use according to claim 1 or 2, wherein the first dose is in the range of 10 μg to 30 μg, the second dose is in the range of 40 μg to 70 μg, and the third dose is in the range of 230 μg to 250 μg.

20. 3. The TCR-anti-CD3 fusion molecule for use according to claim 1 or 2, wherein the first dose is in the range of 10 μg to 30 μg, the second dose is in the range of 40 μg to 70 μg, and the third dose is 240 μg.

21. 3. The TCR-anti-CD3 fusion molecule for use according to claim 1 or 2, wherein the first dose is 20 μg, the second dose is 60 μg and the third dose is 240 μg.

22. 3. The TCR-anti-CD3 fusion molecule for use according to claim 1 or 2, wherein the first dose is in the range of 10 μg to 30 μg, the second dose is in the range of 40 μg to 70 μg, and the third dose is in the range of 250 μg to 270 μg.

23. 3. The TCR-anti-CD3 fusion molecule for use according to claim 1 or 2, wherein the first dose is in the range of 10 μg to 30 μg, the second dose is in the range of 40 μg to 70 μg, and the third dose is 260 μg.

24. 3. The TCR-anti-CD3 fusion molecule for use according to claim 1 or 2, wherein the first dose is 20 μg, the second dose is 60 μg and the third dose is 260 μg.

25. 3. The TCR-anti-CD3 fusion molecule for use according to claim 1 or 2, wherein the first dose is in the range of 10 μg to 30 μg, the second dose is in the range of 40 μg to 70 μg, and the third dose is in the range of 290 μg to 310 μg.

26. 3. The TCR-anti-CD3 fusion molecule for use according to claim 1 or 2, wherein the first dose is in the range of 10 μg to 30 μg, the second dose is in the range of 40 μg to 70 μg, and the third dose is 300 μg.

27. 3. The TCR-anti-CD3 fusion molecule for use according to claim 1 or 2, wherein the first dose is 20 μg, the second dose is 60 μg and the third dose is 300 μg.

28. 3. The TCR-anti-CD3 fusion molecule for use according to claim 1 or 2, wherein the first dose is in the range of 10 μg to 30 μg, the second dose is in the range of 40 μg to 70 μg, and the third dose is in the range of 310 μg to 330 μg.

29. 3. The TCR-anti-CD3 fusion molecule for use according to claim 1 or 2, wherein the first dose is in the range of 10 μg to 30 μg, the second dose is in the range of 40 μg to 70 μg, and the third dose is in the range of 320 μg.

30. 3. The TCR-anti-CD3 fusion molecule for use according to claim 1 or 2, wherein the first dose is 20 μg, the second dose is 60 μg and the third dose is 320 μg.

31. The TCR-anti-CD3 fusion molecule for use according to any one of claims 1 to 30, wherein a further third dose is administered once every 6 to 8 days until treatment is discontinued.

32. The TCR-anti-CD3 fusion molecule for use according to any one of claims 1 to 31, wherein a steroid is administered prior to the first dose, the second dose and / or the third dose.

33. The TCR-anti-CD3 fusion molecule for use according to any one of claims 1 to 32, administered in combination with one or more anti-cancer therapeutic agents.

34. 34. The TCR-anti-CD3 fusion molecule for use according to claim 33, wherein the anti-cancer therapeutic agent is a checkpoint inhibitor.

35. 35. The TCR-anti-CD3 fusion molecule for use according to claim 34, wherein the checkpoint inhibitor is atezolizumab or pembrolizumab.

36. 36. The TCR-anti-CD3 fusion molecule for use according to any one of claims 1 to 35, which is administered in combination with another TCR-anti-CD3 fusion molecule, said other TCR-anti-CD3 fusion molecule comprising a TCR that binds to the gp100 peptide-MHC complex.

37. The TCR-anti-CD3 fusion molecule for use according to claim 36, wherein said other TCR-anti-CD3 fusion molecule is tebentafsp.

38. 38. The TCR-anti-CD3 fusion molecule for use according to any one of claims 1 to 37, wherein the PRAME positive cancer is selected from the group consisting of melanoma, lung cancer, breast cancer, ovarian cancer, endometrial cancer, esophageal cancer, bladder cancer, head and neck cancer, uterine cancer, acute myeloid leukemia, chronic myeloid leukemia and Hodgkin's lymphoma.

39. 39. The TCR-anti-CD3 fusion molecule for use according to claim 38, wherein the melanoma is uveal melanoma or cutaneous melanoma, the lung cancer is non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC), or the breast cancer is triple negative breast cancer (TNBC).

40. 1. A method of treating a PRAME-positive cancer in a patient comprising intravenously administering to the patient a TCR-anti-CD3 fusion molecule, the TCR-anti-CD3 fusion molecule comprising: a TCR alpha chain amino acid sequence of SEQ ID NO: 14, or a TCR alpha chain amino acid sequence having at least 90%, at least 95% or 100% identity to the amino acid sequence of SEQ ID NO: 14; a TCR β chain-anti-CD3 amino acid sequence of SEQ ID NO: 16, or a TCR β chain-anti-CD3 amino acid sequence having at least 90%, at least 95% or 100% identity to the amino acid sequence of SEQ ID NO: 16; wherein the TCR alpha chain variable domain comprises CDR1, CDR2 and CDR3 having the amino acid sequences of SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:5, respectively, and the TCR beta chain variable domain comprises CDR1, CDR2 and CDR3 having the amino acid sequences of SEQ ID NO:9, SEQ ID NO:10 and SEQ ID NO:11, respectively; The method comprises: (a) at least one first dose ranging from 5 μg to 40 μg; (b) at least one second dose ranging from 15 μg to 80 μg, followed by (c) at least one third dose ranging from 60 μg to 400 μg; administering the second dose is higher than the first dose and the third dose is higher than the second dose; The dose is administered once every 6 to 8 days.